Form 4: Anterix CLO Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Anterix Inc.'s Chief Legal Officer, Gena L. Ashe, reported the sale of 6,564 shares of common stock at $21.07 per share under a pre-arranged trading plan.
Summary
- Gena L. Ashe, Chief Legal Officer & Corporate Secretary of Anterix Inc. (ATEX), reported a transaction.
- On November 18, 2025, Ashe sold 6,564 shares of Anterix Common Stock.
- The shares were sold at a price of $21.07 per share.
- Following this transaction, Ashe beneficially owns 13,366 shares of Anterix Common Stock.
- The transaction was made pursuant to a Rule 10b5-1(c) pre-arranged trading plan.
Sentiment
Score: 4
Explanation: The sale by a key executive, even under a 10b5-1 plan, can be interpreted with slight caution by investors, though the pre-arranged nature mitigates immediate negative sentiment. It's not a strong positive or negative signal on its own.
Negatives
- An insider, the Chief Legal Officer, sold a significant number of shares (6,564) of company stock.
- While executed under a 10b5-1 plan, insider sales can sometimes be perceived negatively by the market as they may suggest a desire to diversify holdings or a lack of confidence.
Related Party Transactions
- Gena L. Ashe, Chief Legal Officer & Corporate Secretary, sold 6,564 shares of Anterix Inc. common stock.
Stakeholder Impact
- Shareholders may view the insider sale as a signal, potentially influencing their perception of management's confidence in the company's near-term prospects, despite the 10b5-1 plan.
Key Dates
| Date | Description |
|---|---|
| 11/18/2025 | Date of transaction (sale of common stock) |
| 11/19/2025 | Date Form 4 was signed and filed |
Recommendation
holdWhile an insider sale, the transaction was conducted under a Rule 10b5-1 plan, which suggests it was pre-scheduled and not necessarily a reaction to new, negative information. Without additional context or other significant insider activity, a single planned sale by an executive typically warrants a 'hold' recommendation, as it doesn't provide a strong enough signal for a 'buy' or 'sell' decision on its own.
Keywords
Anterix, ATEX, Insider Sale, Form 4, Gena L. Ashe, Chief Legal Officer, Stock Transaction, 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.